Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US.

Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve the delivery of existing products and the focused physician base.  Despite the relatively large number of patients suffering from GI diseases and disorders, there are only about 12,000 gastroenterologists in the U.S.  Each year, these physicians conduct over 31 million patient visits and write almost 40 million prescriptions.  GI diseases and disorders may limit the absorption of current oral therapies reducing their effectiveness.  By developing nasal formulations of currently approved oral drug products, Evoke intends to provide patients additional treatment options.

The 505(b)(2) New Drug Application (NDA) for Evoke’s lead product candidate, Gimoti, will be resubmitted to FDA for review in the fourth quarter 2019.  The product is intended for the treatment of diabetic gastroparesis.

Evoke has advanced its product development activities by leveraging corporate relationships with many external clinical, CMC, and regulatory experts.  Evoke intends to continue this strategy of developing products in partnership with various global organizations depending upon new acquisitions and appropriate asset investment.